ALKEM vs LINCOLN: Stock Comparison
ALKEM LABORATORIES is the larger company by market capitalisation. ALKEM LABORATORIES shows a higher ROE, a higher dividend yield and faster revenue growth, while LINCOLN PHARMA shows a lower P/E and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ALKEM leads 7; LINCOLN leads 4 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ALKEM | LINCOLN |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | ALKEM | LINCOLN |
|---|---|---|
| Live Price | ₹5,013.5 | ₹510.85 |
| Day Change | -0.03% | -0.72% |
| Volume | 49,335 | 61,149 |
| 52-Week High | ₹5,933.5 | ₹770 |
| 52-Week Low | ₹4,891.5 | ₹440 |
| Distance from 52W High | -15.51% | -33.66% |
Valuation
| Metric | ALKEM | LINCOLN |
|---|---|---|
| Market Cap | ₹59,508 Cr | ₹1,023 Cr |
| P/E Ratio | 27.58x | 10.61x |
| P/B Ratio | 4.31x | 1.35x |
| EPS | ₹180.84 | ₹18.09 |
| Book Value | ₹1,155.87 | ₹378.25 |
| Dividend Yield | 0.4% | 0.35% |
Growth
| Metric | ALKEM | LINCOLN |
|---|---|---|
| Revenue Growth (TTM YoY) | 14.6% | 11.4% |
| EPS Growth (TTM YoY) | -22.7% | 0.6% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | ALKEM | LINCOLN |
|---|---|---|
| ROE | 16.39% | 11.6% |
| ROCE | 11.48% | 10.97% |
| Net Margin | 15.65% | 13.1% |
| Operating Margin | 20.61% | 17.38% |
| Debt to Equity | 0.11x | 0.01x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ALKEM | LINCOLN |
|---|---|---|
| Promoter Holding | 49.7%▼ 1.5 pp | 49.78% |
| FII Holding | 10.42%▲ 0.26 pp | 4.6%▼ 0.59 pp |
| DII Holding | 22.63%▲ 1.23 pp | 0.27%▼ 0.82 pp |
| Public Holding | 17.25% | 45.36%▲ 1.42 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ALKEM LABORATORIES and LINCOLN PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.